Keywords: Teva, OncoGen, Custirsen, Prostate cancer, Fortut-quarter 2011 financial results
Teva and OncoGenex update on prostate cancer drug development; loss widens at latter
Article | 12 March 2012
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals (Nasdaq: OGXI) say they have updated their development ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
